Editas Medicine, Inc. (EDIT)
Nasdaq · Healthcare · Biotechnology
$2.79+6.49%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $429M
- 52-week range
- $1.66 – $4.54
- 52-week change
- −33.33%
- EPS (trailing)
- −$0.72
- Analyst rating
- 1.9 Buy
- Next earnings
- Nov 9, 2026
Fiscal year to Dec 2025
- Revenue
- $40.5M (+25.39%)
- Net income
- −$160M
- Operating margin
- −394.9%
- Diluted EPS
- −$1.80
- Free cash flow
- −$166M
From the company’s annual report on SEC EDGAR.
About Editas Medicine, Inc.
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Headquarters: Cambridge, United States · 87 employees · editasmedicine.com